Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene plus azacitidine versus placebo plus azacitidine in newly diagnosed RARA-positive higher-risk myelodysplastic syndrome
2020-004528-40Phase 3Active
- Sponsor
- Syros Pharmaceuticals
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Tamibarotene plus azacitidine with Placebo plus azacitidine (2 arms). Primary endpoint: Complete remission/complete response rate. Started Feb 2021; status: active.
02
Drugs
tamibaroteneazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-004528-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004528-40.